Canada markets closed

Terns Pharmaceuticals, Inc. (TERN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.16+0.27 (+5.52%)
At close: 04:00PM EDT
4.91 -0.25 (-4.84%)
After hours: 07:45PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close4.89
Open4.87
Bid5.20 x 1400
Ask4.91 x 900
Day's Range4.62 - 5.39
52 Week Range1.45 - 11.30
Volume248,721
Avg. Volume370,049
Market Cap194.087M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Terns Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

    FOSTER CITY, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that management will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14 at 2:00 p.m. ET. A live audio

  • GlobeNewswire

    Terns Announces $65 Million Oversubscribed Offering

    FOSTER CITY, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that it has agreed to sell, by way of an underwritten public offering, 12,250,000 shares of its common stock at a price of $2.42 per share and, to certain i

  • GlobeNewswire

    Terns Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights

    TERN-701 (allosteric BCR-ABL inhibitor) advances into Phase 1 trial for CML in ChinaIND-enabling activities for TERN-601 (GLP-1R agonist) remain on track; Phase 1 obesity trial initiation expected in 2023Initiated dosing of TERN-501 (THR-β agonist) Phase 2a DUET combo clinical trial for NASH; top-line data expected in second half of 2023Cash and equivalents of $140 million provides runway into 2025, supporting three expected clinical trial readouts across three product candidates and three indic